

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
18 January 2024 (18.01.2024)



(10) International Publication Number  
**WO 2024/015503 A1**

(51) International Patent Classification:

C07D 401/04 (2006.01) C07D 487/04 (2006.01)  
C07D 405/12 (2006.01) C07D 519/00 (2006.01)  
C07D 405/14 (2006.01) A61P 25/00 (2006.01)  
C07D 413/04 (2006.01) A61K 31/407 (2006.01)

(21) International Application Number:

PCT/US2023/027610

(22) International Filing Date:

13 July 2023 (13.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/389,482 15 July 2022 (15.07.2022) US

(71) Applicant: **BIOGEN MA INC.** [US/US]; 225 Binney Street, Cambridge, MA 02142 (US).

(72) Inventors: **LOPEZ DE TURISO, Felix, Gonzalez**; c/o Biogen MA Inc., 225 Binney Street, Cambridge, MA 02142 (US). **HIMMELBAUER, Martin**; c/o Biogen MA Inc., 225 Binney Street, Cambridge, MA 02142 (US). **JONES, John, H.**; c/o Biogen MA Inc., 225 Binney Street, Cambridge, MA 02142 (US). **LIN, Edward, Yin Shiang**; c/o Biogen MA Inc., 225 Binney Street, Cambridge, MA 02142 (US). **PRINCE, Robin**; c/o Biogen MA Inc., 225 Binney Street, Cambridge, MA 02142 (US). **PATTAROPONG, Vatee**; c/o Biogen MA Inc., 225 Binney Street, Cambridge, MA 02142 (US). **XIN, Zhili**; c/o Biogen MA Inc., 225 Binney Street, Cambridge, MA 02142 (US).

(74) Agent: **ZHANG, Xin** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF



(I)

(57) Abstract: Provided are compounds of the Formula (I) or pharmaceutically acceptable salts thereof, which are useful for the inhibition of EBP and in the treatment of a variety of EBP mediated conditions or diseases, such as multiple sclerosis.



WO 2024/015503 A1